The Manufacturers Life Insurance Company Increases Holdings in CVS Health Corporation $CVS

The Manufacturers Life Insurance Company boosted its position in CVS Health Corporation (NYSE:CVS) by 0.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,217,244 shares of the pharmacy operator’s stock after purchasing an additional 8,213 shares during the period. The Manufacturers Life Insurance Company owned about 0.10% of CVS Health worth $87,422,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CVS. TOWER TRUST & INVESTMENT Co grew its holdings in CVS Health by 0.8% in the fourth quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock valued at $1,247,000 after purchasing an additional 132 shares during the last quarter. CYBER HORNET ETFs LLC raised its stake in shares of CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after buying an additional 134 shares during the last quarter. LS Investment Advisors LLC boosted its position in shares of CVS Health by 3.9% in the 4th quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock worth $284,000 after buying an additional 135 shares in the last quarter. Moss Adams Wealth Advisors LLC boosted its position in shares of CVS Health by 4.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock worth $239,000 after buying an additional 135 shares in the last quarter. Finally, Northwestern Mutual Investment Management Company LLC grew its stake in CVS Health by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock valued at $3,219,000 after acquiring an additional 136 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Trading Down 3.0%

NYSE CVS opened at $106.02 on Thursday. The firm has a market capitalization of $135.27 billion, a price-to-earnings ratio of 46.70, a PEG ratio of 1.07 and a beta of 0.61. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a one year low of $61.00 and a one year high of $110.68. The company’s 50 day moving average price is $100.99 and its 200 day moving average price is $86.74.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same period in the previous year, the firm earned $2.25 earnings per share. CVS Health’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts predict that CVS Health Corporation will post 7.46 EPS for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.5%. The ex-dividend date is Thursday, July 23rd. CVS Health’s dividend payout ratio is currently 117.18%.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analysts expect CVS Health’s upcoming earnings to show continued growth, with favorable earnings and revenue trends cited as potential catalysts for a beat. The outlook is supported by resilient healthcare demand and the company’s latest reported quarter, when CVS exceeded consensus EPS and revenue estimates. CVS Health Earnings Expected to Grow
• Positive Sentiment: CVS Pharmacy has begun offering common prescription medications for dogs and cats at approximately 9,000 locations, expanding its retail healthcare offering and creating a potential incremental source of pharmacy traffic and revenue. Pet Medications Now Available at CVS Pharmacy
• Positive Sentiment: Health100, a CVS subsidiary, earned DirectTrust accreditation under the CARIN Code of Conduct for consumer-facing applications. The recognition may strengthen confidence in the Health100 app’s data privacy and security, although the near-term financial effect is likely limited. Health100 Earns Industry Accreditation
• Neutral Sentiment: X and the World Federation of Advertisers settled litigation related to an alleged advertiser boycott. CVS was previously identified among companies accused by X, but the settlement appears unlikely to have a material direct effect on CVS’s operations or earnings. X and WFA Settle Litigation
• Negative Sentiment: Potentially ending Medicare Part D subsidies for 2027 is the most significant near-term concern. Investors may be reassessing CVS’s Medicare exposure, even as the company continues to benefit from expectations for earnings growth and recent operating momentum. Potential Medicare Part D Subsidy Changes

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. UBS Group increased their price objective on shares of CVS Health from $115.00 to $122.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft increased their price target on shares of CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Royal Bank Of Canada lifted their price target on shares of CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a report on Thursday, July 9th. Sanford C. Bernstein upped their price objective on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Finally, Truist Financial increased their target price on CVS Health from $108.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Twenty-one equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $105.67.

Insider Activity

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 3,441,551 shares of company stock worth $323,703,977 over the last three months. 0.85% of the stock is currently owned by corporate insiders.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.